期刊
VACCINE
卷 26, 期 2, 页码 215-223出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2007.10.061
关键词
HIV-1; vaccines; cytotoxic T-lymphocyte; DNA plasmid; epitopes; HLA supertypes; interferon-gamma; Botswana
资金
- NIAID NIH HHS [U01-AI-48021-01, P01-AI-48238, U01-AI-46747, U01-AI-48023] Funding Source: Medline
We evaluated EP HIV-1090 vaccine, a DNA plasmid encoding 21 cytotoxic T-lymphocyte (CTL) epitopes of human immunodeficiency virus type 1 (HIV-1) and the pan-DR helper T-lymphocyte epitope (PADRE), in a dose escalation, randomized, double-blinded, placebocontrolled Phase 1 trial. Vaccine, at 0.5, 2.0, or 4.0 mg doses, or placebo was injected four times over 6 months. Forty-two healthy, HIV-1-uninfected adults were enrolled. Using an interferon-gamma ELISPOT assay, a response to PADRE was detected in one vaccine recipient. Three vaccine recipients raised anti-HIV-1 CD8+ CTL measured by chromium-release assay. The vaccine was safe and well-tolerated, but only weakly immunogenic. (c) 2007 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据